Milan Puskar
Keine laufenden Positionen mehr
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Douglas J. Leech | M | 69 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV.
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 25 Jahre |
David Hardesty | M | 78 |
West Virginia University
| 29 Jahre |
Neil Dimick | M | 75 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 19 Jahre |
Randall L. Vanderveen | M | 73 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 22 Jahre |
Sally K. Richardson | F | 91 |
West Virginia University
| 25 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Rajiv Malik | M | 63 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | - |
Heather Bresch | F | 54 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 15 Jahre |
Rodney L. Piatt | M | 71 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 3 Jahre |
Daniel C. Flynn | M | - |
West Virginia University
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 21 Jahre |
Stuart A. Williams | M | 69 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 3 Jahre |
Edwin Roberson | M | 77 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 1 Jahre |
Roderick P. Jackson | M | 83 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 1 Jahre |
Joseph C. Maroon | M | 83 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 14 Jahre |
Clarence B. Todd | M | 90 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 14 Jahre |
Scott Segal | M | 69 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 1 Jahre |
Robert Coury | M | 63 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 5 Jahre |
Wendy Cameron | F | 64 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 5 Jahre |
Harry Korman | M | 66 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 18 Jahre |
Robert Willison | M | 63 |
West Virginia University
| 11 Jahre |
Tony Charles Pintsopoulos | M | - |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 6 Jahre |
James J. Mirasola | M | - |
West Virginia University
| 10 Jahre |
James L. Estep | M | - |
West Virginia University
| 6 Jahre |
James Franklin Miller | M | 68 |
West Virginia University
| 5 Jahre |
Stanley M. Hostler | M | 96 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 1 Jahre |
Ed Borkowski | M | 64 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 10 Jahre |
Daniel E. Crookshank | M | - |
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | - |
Robert A. McMillan | M | 81 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
David Allara | M | - |
West Virginia University
| 8 Jahre |
William C. Wojciechowski | M | - |
West Virginia University
| 2 Jahre |
Charles P. Miller | M | 62 |
West Virginia University
| 7 Jahre |
Zach Thomas Abraham | M | - |
West Virginia University
| 5 Jahre |
Stacey J. Marshall | F | - |
West Virginia University
| 4 Jahre |
Edward Hughes | M | - |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 1 Jahre |
Matthew Powell | M | - |
West Virginia University
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 5 Jahre |
Mark Dehlin | M | - |
West Virginia University
| 7 Jahre |
Patrick K. Marlatt | M | - |
West Virginia University
| 6 Jahre |
Lori J. Paletta-Davis | F | - |
West Virginia University
| 5 Jahre |
Renee Cutright | F | - |
West Virginia University
| 5 Jahre |
Michael Murray | M | - |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
Kevin E Howard | M | - |
West Virginia University
| 6 Jahre |
John E. Golden | M | - |
West Virginia University
| 6 Jahre |
Joseph F. Haggerty | M | - |
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | - |
Steven A. Antoline | M | 67 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 7 Jahre |
Louis J. DeBone | M | 78 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | 30 Jahre |
Carolyn Myers | M | 66 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 4 Jahre |
Paul T. Swanson | M | 91 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
Richard Rappaport | M | 64 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 6 Jahre |
Roger Foster | M | 77 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | 23 Jahre |
Bernard G. Westfall | M | 82 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
N. Prasad | M | 61 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | - |
Parry G. Petroplus | M | 72 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
Kevin D. Lemley | M | 69 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
Sean S. H. Wang | M | - |
West Virginia University
| - |
Larry Gale McClanahan | M | 67 |
West Virginia University
| 6 Jahre |
Arthur Gabriel | M | 85 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
James W. Dailey | M | 77 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
C. Christopher Cluss | M | 76 |
Centra Financial Holdings, Inc.
Centra Financial Holdings, Inc. Financial ConglomeratesFinance Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV. | - |
Stephen C. Turner | M | 78 |
SRKP 5, Inc.
SRKP 5, Inc. Miscellaneous Commercial ServicesCommercial Services SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. | 1 Jahre |
Maria Lacerca-Allen | M | 57 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | - |
Mark Parrish | M | 68 |
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | - |
Daniel C. Rizzo | M | 61 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | 1 Jahre |
Tamar Frumkin | F | - |
West Virginia University
| 4 Jahre |
Nick Scarsella | M | - |
West Virginia University
| 4 Jahre |
Charles Crimmel | M | 50 |
West Virginia University
| 4 Jahre |
Joseph M. Menendez | M | 50 |
West Virginia University
| 5 Jahre |
Chris Beres | M | - |
West Virginia University
| 4 Jahre |
Jason Belcher | M | 47 |
West Virginia University
| 4 Jahre |
Michael Sarver | M | 47 |
West Virginia University
| 4 Jahre |
Seok-Joo Lee | M | 63 |
West Virginia University
| 4 Jahre |
Trisha L. Fox | F | 54 |
West Virginia University
| 1 Jahre |
Justin Miller | M | - |
West Virginia University
| 4 Jahre |
Diana Charletta | F | 51 |
West Virginia University
| 4 Jahre |
Theo Gibson | M | - |
West Virginia University
| 4 Jahre |
Anil S Menawat | M | - |
West Virginia University
| 2 Jahre |
Nicholas Wright | M | - |
West Virginia University
| 4 Jahre |
John Ingrassia | M | - |
West Virginia University
| 4 Jahre |
John Cammarano | M | - |
West Virginia University
| 4 Jahre |
Randy Hefner | M | - |
West Virginia University
| 4 Jahre |
Jamie Walters | M | - |
West Virginia University
| 4 Jahre |
Bhushan Kulkarni | M | - |
West Virginia University
| 4 Jahre |
Xiang Dong Zou | M | 66 |
West Virginia University
| 3 Jahre |
Brian Turley | M | - |
West Virginia University
| 4 Jahre |
Lou Schiliro | M | 51 |
West Virginia University
| 4 Jahre |
Jason H. Scott | M | - |
West Virginia University
| 3 Jahre |
David A. Robaugh | M | - |
West Virginia University
| 3 Jahre |
Jay R. Henry | M | - |
West Virginia University
| 5 Jahre |
John Pinion | M | 58 |
West Virginia University
| 4 Jahre |
Michele Smith | F | - |
West Virginia University
| 4 Jahre |
Marty Becker | M | 71 |
West Virginia University
| 4 Jahre |
Tina L. Mascaro | F | - |
West Virginia University
| 4 Jahre |
Brian Alan Robinette | M | - |
West Virginia University
| 2 Jahre |
Brian Cleek | M | - |
West Virginia University
| 4 Jahre |
Brent Clark | M | - |
West Virginia University
| 5 Jahre |
Mark Pack | M | - |
West Virginia University
| 4 Jahre |
George L. Ford | M | 54 |
West Virginia University
| 4 Jahre |
David McLaughlin | M | - |
West Virginia University
| 5 Jahre |
Le Jiang Xu | M | 65 |
West Virginia University
| 1 Jahre |
Gary H. Maxwell | M | - |
West Virginia University
| 3 Jahre |
H. Jude | M | - |
West Virginia University
| 1 Jahre |
Tim Deer | M | - |
West Virginia University
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Milan Puskar
- Persönliches Netzwerk